Table 4. Stratified analysis of the recurrence-free survival of four-lncRNA signature in the training set and testing set.

Variable	Training set			Testing set
	Number	HR	P	Number	HR	P
	(High/Low)	(95% CI)	value	(High/Low)	(95% CI)	value
Gender
Female	6/7	5.765 (0.64–51.95)	0.078	6/7	7.811 (0.801–76.15)	0.077
Male	45/45	2.166 (1.217–3.854)	0.0071*	38/49	2.072 (1.224–3.508)	0.0056*
Age
<60	45/35	2.34 (1.214–4.51)	0.0089*	34/47	1.954 (1.102–3.464)	0.02*
≥60	6/17	3.758 (1.149–12.29)	0.019*	9/9	4.428 (1.19–16.47)	0.015*
ALT
≤50 U/L	27/34	2.164 (1.08–4.333)	0.026*	22/32	1.974 (0.947–4.115)	0.064
>50U/L	24/18	2.852 (1.102–7.379)	0.024*	22/24	2.394 (1.179–4.86)	0.013*
Main Tumor Size
≤5 cm	32/36	3.655 (1.725–7.745)	0.0003*	21/37	1.95 (1.018–3.735)	0.04*
>5 cm	18/16	1.324 (0.571–3.07)	0.51	23/19	2.586 (1.079–6.199)	0.028*
Multinodular
NO	39/47	2.514 (1.382–4.573)	0.0018*	30/44	2.516 (1.379–4.592)	0.0019*
YES	12/5	1.596 (0.329–7.749)	0.56	14/12	1.658 (0.635–4.331)	0.3
TNM stage
I+II	37/45	2.608 (1.357–5.01)	0.0028*	24/47	2.837 (1.524–5.282)	0.00061*
III	14/7	1.214 (0.42–3.512)	0.72	19/8	1.167 (0.428–3.184)	0.77
BCLC stage
0+A	36/47	2.658 (1.385–5.104)	0.0023*	26/43	2.671 (1.41–5.058)	0.0018*
B+C	15/5	0.564 (0.187–1.7)	0.3	17/12	1.608 (0.668–3.872)	0.29
AFP
≤300 ng/ml	21/33	2.228 (1.073–4.625)	0.027*	17/35	3.615 (1.692–7.724)	0.00042*
>300 ng/ml	29/17	2.489 (0.991–6.255)	0.0524	27/21	1.426 (0.704–2.89)	0.32

Notes.

^*Statistically significant.

Abbreviations

BCLC stage

Barcelona Clinic Liver Cancer stage

Multinodular

whether the tumor has multiple nodules

HR

hazard ratio

95%CI

95% confidence interval